A randomised double-blind study in two parts Part A - Comparing two humanized monoclonal antibodies that target VEGF in combination with mFOLFOX6 in patients with non-resectable metastatic colorectal cancer (mCRC) and Part B - Comparing two humanized monoclonal antibodies that target VEGF in combination with pemetrexed and carboplatin in recurrent or advanced nonsquamous non-small cell lung cancer (NSCLC) - BZ-01-002

Trial Profile

A randomised double-blind study in two parts Part A - Comparing two humanized monoclonal antibodies that target VEGF in combination with mFOLFOX6 in patients with non-resectable metastatic colorectal cancer (mCRC) and Part B - Comparing two humanized monoclonal antibodies that target VEGF in combination with pemetrexed and carboplatin in recurrent or advanced nonsquamous non-small cell lung cancer (NSCLC) - BZ-01-002

Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Aug 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin; Fluorouracil; Folinic acid; Oxaliplatin; Pemetrexed
  • Indications Colorectal cancer; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Dr Reddys Laboratories
  • Most Recent Events

    • 26 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top